The German government's proposed measures to curb spending in the statutory health insurance system (GKV) are facing criticism from pharmaceutical manufacturers and legal experts, who argue that the reforms could have significant constitutional implications.

Government Aims to Stabilize Health Insurance Contributions

The federal government has introduced the Contribution Rate Stabilization Act (BStabG), which is set for its first reading in the Bundestag. The primary objective is to reduce the financial burden on statutory health insurers by approximately 16.3 billion euros, thereby preventing increases in supplementary contributions from insured individuals. Pharmacies will also contribute through an increased discount to the health funds, rising by 30 cents to 2.07 euros per prescription.

Dynamic Manufacturer Discount Under Scrutiny

A key component of the legislation is a plan to adjust the existing manufacturer discount, currently set at seven percent, by introducing a dynamic element linked to the ratio of pharmaceutical expenditure to GKV revenues. This adjustment would mean that the discount could increase automatically if costs rise, without time limitation. The pharmaceutical association, Pharma Deutschland, has raised strong objections, warning that such measures could weaken Germany as a pharmaceutical production location. Major companies have responded by reconsidering their investment strategies in Germany. For example, Eli Lilly announced a reduction in planned investment for a new facility in Alzey, and Boehringer Ingelheim has halted planned investments totaling 900 million euros in the country.

Legal Opinion Questions Proportionality of Measures

In anticipation of the parliamentary debate, Pharma Deutschland commissioned a legal analysis to evaluate the proposed measures' compliance with constitutional standards. According to the legal experts, the new cost-saving strategies exceed previous interventions approved by the Federal Constitutional Court (BVerfG). The court had previously deemed measures in the 2022 GKV Financial Stabilization Act, such as a temporary increase in the manufacturer discount and an extension of the price moratorium, to be proportionate.

However, the current proposal's dynamic, potentially unlimited increase in the manufacturer discount is seen by legal analysts as surpassing the threshold of moderate financial burden established by the court. The experts emphasize that the lack of legislative oversight on each step of the discount's increase could result in excessive and unchecked financial pressure on manufacturers, raising constitutional concerns regarding proportionality and legislative control.

Potential Systemic Impact on Drug Pricing and Supply

Additional legal concerns relate to planned cluster tenders for patent-protected medicines with similar therapeutic effects. The draft law would allow health insurers to initiate exclusive or cross-active ingredient tenders for rebate contracts on such drugs. Physicians would be required to prescribe the discounted products preferentially. Legal experts warn that this approach could fundamentally alter the existing system of drug evaluation and pricing, potentially undermining the established benefit assessment process under the AMNOG procedure.

Critics argue that these changes could disrupt the balance between cost control and access to innovative therapies, while also reducing Germany's attractiveness as a location for pharmaceutical research and production. The pharmaceutical sector has already begun to signal a reduction or withdrawal of planned investments in response to the proposed law.

Industry and Political Dialogue Intensifies

In recent discussions with parliamentary health officials, industry representatives have called for closer cooperation between the government and pharmaceutical companies to ensure stable supply chains and maintain patient access to essential medicines. The ongoing debate highlights the need for policy solutions that balance fiscal responsibility with the sustainability of the pharmaceutical industry and the broader healthcare system.